Table 2.

Drug sensitivity IC₅₀-values and Relative resistance

Anti- cancer drugs	Epirubicin	RR	Docetaxel	RR	Cisplatin	RR	LMP776	RR	LMP400	RR
MDAacq DMSO	0.4 ± 0.2	4.3	22.0 ± 9.9	1.0	62.8 ± 13.7	1.1	8.9 ± 11.7	5.0	10.5 ± 9.7	1.2
MDAacq	1.7 ± 0.3		21.0 ± 5.3		70.6 ± 4.1		44.6 ± 45.7		12.4 ± 12.2
MCF-7acq DMSO	0.9 ± 0.5	1.9	20.4 ± 2.3	1.3	26.1 ± 9.5	2.5	a		a
MCF-7acq	1.7 ± 0.9		25.8 ± 8.2		65.6 ± 53.4		a		a
MDAde novo DMSO	5.2 ± 3.2	3.4	18.0 ± 3.7	1.5	34.7 ± 7.03	2.7	11.0 ± 6.2	2.0	15.8 ± 6.3	1.6
MDAde novo	17.6 ± 1.4		27.3 ± 2.1		95.1 ± 4.9		22.5 ± 4.3		25.8 ± 3.5
MCF-7de novo DMSO	8.1 ± 9.1	1.2	24 ± 7.5	1.5	45.6 ± 5.4	1.2	40.0 ± 14.2	1.4	42.6 ± 36.3	1.4
MCF-7de novo	10.0 ± 7.9		34.9 ± 10.2		53.7 ± 13.0		55.9 ± 28.6		58.2 ± 36.5

Mean IC₅₀-value (μM) ± standard deviation of three independent experiments. RR; relative resistance is the IC₅₀-value of the resistant cell line divided by the IC₅₀-value of their corresponding DMSO controls ^aCross-resistance by looking at the graphs as 50 % inhibition was not achieved with these drugs